Company intelligence / Profile preview
Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd.
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple products in clinical development, with SSGJ-608 (anti-IL-17A monoclonal antibody) having completed Phase 3 clinical study for psoriasis with data expected in Q4 2023. The company plans to submit an application for listing in 2024. Other products include SSGJ-707 (PD-1 x VEGF bispecific antibody) and HBT-708 in Phase 1 for advanced malignant solid neoplasms[1][9].
- Therapeutic areas
- OncologyDermatologyImmunology
- Modalities
- Bispecific antibodyBiological productsMonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dansheng Pharmaceutical Technology (Shanghai) Co., Ltd..